AstraZeneca (AZN) said Monday that a final overall survival analysis of its phase 3 study for patients with 1st line locally advanced or metastatic epidermal growth factor receptor-mutated, or EGFRm, non-small cell lung cancer showed improvement in key secondary endpoints.
The FLAURA2 phase 3 study evaluated Tagrisso in combination with pemetrexed and platinum-based chemotherapy in patients with EGFRm lung cancer.
"Tagrisso plus chemotherapy demonstrated statistically significant and clinically meaningful improvement in overall survival in EGFR-mutated advanced lung cancer," the company said.
The latest analysis is in line with the interim overall survival report and builds on the previously presented primary endpoint data, which demonstrated the longest-reported median progression-free survival in this setting, AstraZeneca said.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。